Figure 2 below illustrates key therapeutic targets in the EGFR, KRAS, BRAF, and PI3K/AKT/mTOR pathways, with inhibitors that can block critical nodes in colorectal cancer progression. This evidence concerns the gene EGFR and colorectal cancer.